1.
Cardiovasc Revasc Med
; 32: 69-74, 2021 11.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33514487
RESUMEN
Percutaneous intervention in the context of coronary artery ectasia (CAE) is penalized with no-reflow phenomenon. The glycoprotein-IIb/IIIa-inhibitor abciximab was the most accepted method for pharmacology thrombus resolution in this scenario, nevertheless, this agent was recently withdrawn. We describe 5 patients treated with local intracoronary fibrinolysis administrated through predesigned catheters in the setting of AMI and CAE.